Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Articles|August 30, 2021
Dermavant Moves One Step Closer to Potential New Treatment Option for Patients with Plaque Psoriasis
Author(s)Dermavant
Advertisement
Partner Perspectives
Dermavant Sciences recently announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.
Message from Dermavant CEO, Todd Zavodnick
Advertisement
Related to this article
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
4
Tolerability and Response Criteria Guide Hedgehog Inhibitor Choice in Advanced BCC
5